Topics:

Leukemia & Lymphoma

FDA Approves Blinatumomab for Acute Lymphoblastic Leukemia

The FDA has approved blinatumomab (Blincyto) for the treatment of patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia.

Leukemia & Lymphoma

The FDA has expanded the approved use of ibrutinib (Imbruvica) to include patients with Waldenström macroglobulinemia, a rare type of non-Hodgkin lymphoma.

In a recent study of pediatric ALL, minimal residual disease was able to predict patients who were at increased risk for relapse post-allogeneic stem cell transplantation.

Using genome-wide association studies, researchers have identified a germline variant that is associated with intolerance to mercaptopurine in pediatric ALL.

Socioeconomic factors are reducing the use of combined-modality treatment for early-stage Hodgkin lymphoma, despite its association with increased survival.

In its Annual Report on Progress Against Cancer, ASCO has declared that the transformation in the treatment of patients with CLL is the “advance of the year.”

Long-term follow-up confirmed the previously reported result that intermittent administration of imatinib is safe and effective in CML patients.

Despite the early trial termination due to safety concerns, an analysis suggests that ponatinib offers improved efficacy over imatinib in newly diagnosed CML.

Pages

Subscribe to Leukemia & Lymphoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.